JNJ Related Hot List
-
J&J (JNJ) Reports In-Line Q2 EPS of $1.30; Cuts FY12 Outlook
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 2c; Raises FY12 EPS Guidance
-
Johnson & Johnson (JNJ) Tops Q4 EPS by 3c; Guides FY12 Below the Street
-
Johnson & Johnson (JNJ) Tops Q2 EPS by 5c; Reaffirms Guidance
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 9c; Raises FY11 Outlook
-
Johnson & Johnson (JNJ) Reports In-Line Q4 EPS of $1.03; Guides FY11 Below the Street
-
Smith & Nephew (SNN) Surges On Reports of Johnson & Johnson (JNJ) Takeover Bid
-
13F from Buffett's Berkshire Shows New Stake in BK, Raised Stakes in WFC, JNJ, Lowered Stakes in PG, IR
-
Johnson & Johnson (JNJ) Reports Q3 EPS of $1.23, Beats by 8c; Raises FY10 Outlook
-
Crucell (CRXL) In Advanced Talks to Be Acquired by Johnson & Johnson for $2.3 Billion
-
S&P Announces Changes to S&P SmallCap 600 Index: MPWR for MEND
-
J&J (JNJ) Reports Inline Q2 Adj-EPS of $1.21; Cuts FY10 EPS Guidance
-
J&J (JNJ) to acquire Micrus (MEND) for $23.40/share
-
J&J (JNJ) Reports Q1 Adj-EPS of $1.29, Beats by 2c; Slightly Lowers FY10 EPS Outlook
-
Johnson & Johnson (JNJ) Reports Q4 Adj-EPS of $1.02, Beats by 5c; Guides FY10 EPS
-
J&J (JNJ) Gets FDA Warning Letter for Delayed Report of Tainted Pills
-
Palomar Medical (PMTI) Slammed After J&J Terminates Agreement On Wrinkle Treatment Laser Device
-
Johnson & Johnson (JNJ) Reports Q3 EPS of $1.20, Beats by 7c; Raises FY09 EPS Guidance
-
J&J (JNJ) and Crucell (CRXL) Announce Strategic Collaboration, J&J Acquires 18% Stake
-
Johnson & Johnson (JNJ) Tops Q2 EPS View by 4c; Reaffirms Outlook
-
Johnson & Johnson (JNJ) To Acquire Alzheimer's Assets From Elan (ELN), Invests $1B For 18.4% Stake
-
JNJ (NYSE: JNJ) to Buy 18.4% Stake In Elan (NYSE: ELN) for $1B
-
FDA Panel Votes 21-16 To Recommend Lowering Maximum Daily Dosage of Johnson & Johnson's (JNJ) Tylenol
-
Johnson & Johnson's (JNJ) Wins $1.67B Patent Verdict Versus Abbott Laboratories (ABT)
-
Johnson & Johnson (JNJ) To Acquire Cougar Biotechnology (CGRB) For $43/Share
-
Johnson & Johnson (JNJ) Reports Q1 EPS of $1.26, Beats by 4c; Reaffirms Outlook
-
Warren Buffett Has Worst Year Ever, In Market He's "Never Before Witnessed"
-
Johnson & Johnson (JNJ) Reports Q4 Adj-EPS of $0.94, Beats by 2c; Guides FY09
-
S&P Announces Changes to US Indices: LSTR for PSUN, ASEI for LSTR, BLUD for FBN, AVAV for BLUD, BRLI for MNT
-
Mentor (MNT) Agrees To Be Acquired By Johnson & Johnson (JNJ) for $31/Share
-
JNJ (JNJ) buys Mentor Corp. (MNT) for $31 per share
-
Johnson & Johnson To Acquire Omrix Biopharmaceuticals (OMRI) For $25/Share
-
Johnson & Johnson (JNJ) Tops Street's Q3 Views; Raises FY08 Outlook
-
Johnson & Johnson (JNJ) Reports Q2 EPS of $1.18, Beats by 6c; Guides
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 6c
-
Johnson & Johnson (JNJ) Tops Q4 EPS by 2c; Reaffirms Guidance
-
Johnson & Johnson (JNJ) Tops Q4 EPS by 7c; Guides Above
-
Isis Pharma (ISIS) Announces Broad Collaboration with Johnson & Johnson's Ortho-McNeil
-
Amgen (AMGN), Johnson & Johnson (JNJ) anemia drug doses shouldn't be lower, panel says - Bloomberg
-
Johnson & Johnson (JNJ) Tops Q2 EPS by 5c
-
UPDATE: Johnson & Johnson (JNJ) confirms $10 billion buyback
-
FDA panel votes 15-2 in favor of more restrictions on Amgen (AMGN) and Johnson & Johnson (JNJ) anemia drugs
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 11c
-
Stents Fail to Cut Heart Attacks Better Than Drug Therapy From 'Courage' Study - Bloomberg
-
Johnson & Johnson (JNJ) Tops Q4 EPS by 2c
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 5c
-
Vertex Pharma (VRTX) and JNJ Company Janssen in Deal to Develop and Commercialize VX-950
-
Johnson & Johnson (JNJ) Near Deal for Pfizer's Consumer Unit - NYT
-
Sepracor (SEPR) Spokeswomen 'No Comment' On Takeover Talk, Shares Surge
-
Boston Scientific (BSX) Said Court Upholds Verdict Against Johnson & Johnson (JNJ)
Back to JNJ Stock Lookup
